Deerfield Mgmt III, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1610540. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-02-08 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 3 filings — 18,665,617 shares, $92,499,993 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 2 filings — 1,303,419 shares, $23,806,856 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: purchase of 1,430,206 shares @ $8.74 ($12,500,000) in Larimar Therapeutics, Inc., filed 2024-02-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | Director, 10% owner | 3 | 10 legs · 18,665,617 sh · $92,499,993 | — | — |
| ARS Pharmaceuticals, Inc. (SPRY) | 10% owner | 2 | — | 10 legs · 1,303,419 sh · $23,806,856 | — |
| Parabilis Medicines, Inc. (PBLS) | 10% owner | 1 | — | — | 16 |
| Fractyl Health, Inc. (GUTS) | 10% owner | 1 | — | — | 4 |
Form 4 filings — Deerfield Mgmt III, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with Flynn James E, Deerfield Mgmt HIF, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund III, L.P. | Conversion (C): 122,990 · Conversion (C): 122,990 · Conversion (C): 149,238 · Conversion (C): 149,238 · Conversion (C): 260,992 · Conversion (C): 260,992 · +10 more | EDGAR |
| 2026-03-02 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with Flynn James E, DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 1,084,010 @ $5 · Purchase (P): 1,084,012 @ $5 · Purchase (P): 831,978 @ $5 · Purchase (P): 2,000,000 @ $5 | EDGAR |
| 2025-08-04 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with Flynn James E, DEERFIELD MANAGEMENT COMPANY, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 3,387,529 @ $3.20 · Purchase (P): 3,387,539 @ $3.20 · Purchase (P): 2,599,932 @ $3.20 | EDGAR |
| 2025-07-01 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with Flynn James E, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 370,075 @ $18.46 · Sale (S): 370,074 @ $18.46 | EDGAR |
| 2024-11-13 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with Flynn James E, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P. | Sale (S): 40,596 @ $17.45 · Sale (S): 40,596 @ $17.45 · Sale (S): 223,632 @ $18.15 · Sale (S): 223,632 @ $18.15 · Sale (S): 7,853 @ $17.16 · Sale (S): 7,854 @ $17.16 · +2 more | EDGAR |
| 2024-02-16 | 4 | Larimar Therapeutics, Inc. (LRMR) jointly with Flynn James E, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., DEERFIELD PARTNERS, L.P. | Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,206 @ $8.74 · Purchase (P): 1,430,205 @ $8.74 | EDGAR |
| 2024-02-08 | 4 | Fractyl Health, Inc. (GUTS) jointly with Flynn James E, Deerfield Private Design Fund III, L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Conversion (C): 757,548 · Conversion (C): 76,706 · Conversion (C): 1,625,699 (derivative) · Conversion (C): 164,612 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1610540 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →